ClinicalTrials.gg
Active, not recruitingNCT05227105Updated Aug 18, 2026

PA Moves Trial - Patient Participants

An interventional study of Physical Activity and Delayed intervention in Overweight or Obesity, Diabetes Mellitus, Type 2 and Physical Inactivity, sponsored by University of Pittsburgh. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Obesity by University of Pittsburgh — 2 open to participants now, 7 under way, none of them phase 3. Obesity · University of Pittsburgh.

Enrollment
Largest of 49
640 · median 75
Started
2023
with 2 others
No phase
37 of 60
2 open now
Registered
56th of 60
by date

Among the 60 studies in Obesity by University of Pittsburgh, this one has the largest enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2023, is one of 37 with no phase, and was the 56th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 60 studies in Obesity by University of Pittsburgh are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Obesity by University of Pittsburgh, or all of them as a file.
02

Study summary

The purpose of this study is to address physical inactivity in rural populations in Pennsylvania.

Read the detailed description

People living in rural areas are diagnosed and die from cancer at higher rate than people living in cities. Physical activity has been shown to decrease the risk and occurrence of a variety of cancers, including bladder, breast, colon, endometrial, gastric, kidney, and prostate cancers. Being inactive can cause over 10% of breast and colon cancer cases.

Compared to people living in cities, people living in rural areas tend to be less physically active. They're also more likely to be overweight/obese or have diabetes. Adults who are overweight, obese, or diabetic often have changes in the way their bodies deal with insulin, glucose metabolism, and inflammation. Physical activity is thought to reduce the risk of cancer by improving these issues over time.

Primary care providers and their staff can identify a patient's need for more physical activity, but may not have the time or resources to give advice or assistance. We have set up a telephone-based physical activity coaching program, called the MoveLine, to give inactive patients advice and assistance in becoming more physically active.

The purpose of this study is to determine if referring inactive patients to the MoveLine will help them to be more physically active over time. Approximately 880 people will take part in this research in rural areas of Pennsylvania.

03

Conditions studied

  • Overweight or Obesity
  • Diabetes Mellitus, Type 2
  • Physical Inactivity

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's enrollment of 640 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,422 studies on the registry; 170 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 - 75 at the time of enrollment
  • Either overweight/obese ( (BMI) ≥ 25) or diabetic ( ≥ 5.7%)
  • Physically inactive (defined as \< 90 min/week of self-reported structured physical activity)
  • Able to speak, read, and understand the English language
  • Resides in a rural area of Pennsylvania with a Rural Urban Continuum Code (RUCC) 4 - 9 or Rural-Urban Commuting Area (RUCA) code 4 - 10
  • Must be able to provide and understand
  • Primary care patient of one of the participating providers
  • Self-report ability to walk ¼ mile
  • Access to a telephone

Exclusion criteria

Exclusion Criteria:

  • Cardiac exclusion criteria: Class II, III, or IV heart failure as defined by the (NYHA) functional classification system, history of acute coronary syndromes, uncertain or uncontrolled arrhythmia, uncontrolled hypertension, syncope, acute myocarditis, acute pericarditis, acute endocarditis, acute pulmonary embolus or pulmonary infarction, thrombosis of lower extremities, suspected dissecting aneurysm, pulmonary edema, respiratory failure, or acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise
  • Mental impairment leading to inability to cooperate, provide , or follow study instructions
  • Evidence in the electronic medical record of an absolute for physical activity
  • Severe or advanced orthopedic conditions
  • Use of assistive devices for ambulation
  • Resides outside of a rural area of Pennsylvania (i.e., one that is not RUCC code 4 - 9 OR RUCA code 4 - 10)
  • Pregnant women
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
640 participants (actual)

Study arms

  • Active comparator
    Physical Activity intervention

    Five physical activity coaching calls with MoveLine and weekly physical activity. Objective tracking of activity with an accelerometer will occur at baseline, after 12 months, and after 24 months.

    Behavioral: Physical Activity

  • Placebo comparator
    Delayed intervention

    Objective tracking of activity with an accelerometer will occur at baseline, after 12 months, and after 24 months.

    Behavioral: Delayed intervention

Interventions

  • BehavioralPhysical Activity

    Physical activity will be encouraged up to an amount of 150 minutes per week.

  • BehavioralDelayed intervention

    Physical activity will be encouraged at the end of the trial.

07

What researchers measure

Primary outcomes

  1. Physical Activity Questionnaire

    The 11-question Morgenstern Physical Activity Questionnaire (PAQ-M) is a self-report of physical activity resulting from recreational activities, exercises, home or work activities, and chores.

    Time frame: 12 months vs. baseline

  2. Objective accelerometry

    An accelerometer will be worn for one week to track physical activity.

    Time frame: 12 months vs. baseline

Secondary outcomes

  1. Physical Activity Questionnaire

    The 11-question Morgenstern Physical Activity Questionnaire (PAQ-M) is a self-report of physical activity resulting from recreational activities, exercises, home or work activities, and chores.

    Time frame: 24 months vs. baseline; 24 months vs. 12 months

  2. Objective accelerometry

    An accelerometer will be worn for one week to track physical activity.

    Time frame: 24 months vs. baseline; 24 months vs. 12 months

08

Study locations

1 site
09

References and documents

Publications

  • West SM, Meyer MRU, Patterson C, Ruffin MT, Calo W, Pagoto S, Conroy D, Doerksen S, Sciamanna CN, Gordon B, Garrow G, Werts-Pelter SJ, Schmitz KH. Increasing physical activity in rural Pennsylvanians: The PA moves trial study protocol for a cluster randomized controlled trial. Contemp Clin Trials. 2026 Jul;166:108348. doi: 10.1016/j.cct.2026.108348. Epub 2026 May 13. PubMed 42134685 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Aug 2027, 51 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 51 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 7, 2022
StartActual
May 23, 2023
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05227105
Responsible party
Kathryn Schmitz (Professor, University of Pittsburgh) — Principal investigator
First posted
Feb 7, 2022
Start date
May 23, 2023
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 18, 2026

Study contacts

Kathryn Schmitz, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion